#137 – Hot Topics: What You May Have Missed in Infectious Diseases 2025-2026 (LIVE from MAD-ID)
BreakpointsShow Notes
In this must-listen episode, Dr. Ryan Moenster and Dr. Megan Klatt dive deep into the latest infectious diseases trials, guidelines, and novel therapeutics. Staying current in the field is a challenge, but this podcast episode does the legwork for you.
Note: BCIDP credit is available for this episode.
Google Drive to Slides from Live Session: [https://drive.google.com/file/d/11uHzZoValckfsjUTIdVyAJ35QDSVRfQu/view?usp=sharing](https://drive.google.com/file/d/11uHzZoValckfsjUTIdVyAJ35QDSVRfQu/view?usp=sharing "https://drive.google.com/file/d/11uHzZoValckfsjUTIdVyAJ35QDSVRfQu/view?usp=sharing")
How to Obtain BCIDP Recertification Credit for this Episode: Visit https://sidp.org/BCIDPhttps://sidp.org/BCIDPSIDP - BCIDP Recertification for more information
SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member
Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/
More from Breakpoints
Does oseltamivir harm critically ill patients with influenza? In this Breakpoints and Communicable collaboration, Erin McCreary and Josh Davis are joined by Steve Webb and Steve Tong to discuss the REMAP-CAP trial results that are challenging a long-standing intensive care practice. Together, they review the study design, key findings, and implications for clinical care, while highlighting the importance of randomized clinical trials in shaping evidence-based medicine. At the time of recording, the REMAP-CAP results were available as a preprint.
Dr. Prathit Kulkarni, lead author of a recent state-of-the-art review on acute and chronic bacterial prostatitis, joins host Dr. Erin McCreary to discuss this complex disease state. They walk through diagnosis, epidemiology, treatment, and more. You won’t want to miss this episode!
Gram-negative resistance is beautifully intricate, scientifically elegant, and very complex. Nothing is more exciting than the recently approved and bursting pipeline of beta-lactamase inhibitors. Listen to Drs. Sam Aitken and Christophe Le Terrier, along with host Dr. Erin McCreary, describe the nuanced enzymology and other antibacterial properties of beta-lactamase inhibitors. This episode also discusses the concepts of stand-alone inhibitors, resistance development, and more. If you want to learn more about sulbactam, clavulanic acid, tazobactam, avibactam, relebactam, vaborbactam, durlobactam, enmetazobactam, zidebactam, nacubactam, ledaborbactam, taniborbactam, and xeruborbactam – this episode is for you!